{"prompt": "['Creatinine increased > ULN to', 'monitoring', '1.5 X ULN', 'If worsens:', 'Treat as Grade 2 to 3 or 4.', 'Grade 2 to 3', 'Withhold avelumab therapy', 'If returns to Grade <1:', 'Creatinine increased > 1.5 and', 'Increase frequency of monitoring to', 'Taper steroids over at least 1', 'VI 6x ULN', 'every 3 days', 'month, and resume avelumab', '1.0 to 2.0 mg/kg/day prednisone or', 'therapy following steroids taper.', 'equivalent.', 'If worsens:', 'Add prophylactic antibiotics for', 'Treat as Grade 4.', 'opportunistic infections', 'Consider renal biopsy', 'If returns to Grade 1:', 'Grade 4', 'Permanently discontinue avelumab', 'Taper steroids over at least 1', 'Creatinine increased > 6x ULN', 'therapy', 'month.', 'Monitor creatinine daily', '1.0 to 2.0 mg/kg/day prednisone or', 'equivalent.', 'Add prophylactic antibiotics for', 'opportunistic infections', 'Consider renal biopsy', 'Nephrology consult', 'Cardiac irAEs', 'Myocarditis', 'Initial Management', 'Follow-up Management', 'New onset of cardiac signs or', 'Withhold avelumab therapy.', 'If symptoms improve and', 'symptoms and / or new', 'Hospitalize.', 'immune-mediated etiology', 'laboratory cardiac biomarker', 'In the presence of life threatening', 'is ruled out, re-start', 'elevations (e.g. troponin, CK-', 'cardiac decompensation, consider', 'avelumab therapy.', 'MB, BNP) or cardiac imaging', 'transfer to a facility experienced in', 'abnormalities suggestive of', 'advanced heart failure and arrhythmia', 'If symptoms do not', 'myocarditis.', 'management.', 'improve/worsen, viral', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '33']['Cardiology consult to establish', 'myocarditis is excluded, and', 'etiology and rule-out immune-', 'immune-mediated etiology', 'mediated myocarditis.', 'is suspected or confirmed', 'Guideline based supportive treatment', 'following cardiology', 'as per cardiology consult.', 'consult, manage as immune-', 'mediated myocarditis.', 'Consider myocardial biopsy if', 'recommended per cardiology consult.', 'Immune-mediated', 'Permanently discontinue avelumab.', 'Once improving, taper', 'myocarditis', 'Guideline based supportive treatment', 'steroids over at least 1', 'as appropriate as per cardiology', 'month.', 'consult.*', '1.0 to 2.0 mg/kg/day prednisone or', 'If no improvement or', 'equivalent', 'worsening, consider', 'Add prophylactic antibiotics for', 'additional', 'opportunistic infections.', 'immunosuppressants (e.g.', 'azathioprine, cyclosporine', 'A).', '*Local guidelines, or eg. ESC or AHA guidelines', 'ESC guidelines website:  https://www.escardio.org/Guidelines/Clinical-Practice-Guideline', 'AHA guidelines website:', 'ttp://professional.heart.org/professional/GuidelinesStatements/searchresults.jsp?q=&y=&t=1001', 'Endocrine irAEs', 'Endocrine Disorder', 'Initial Management', 'Follow-up Management', 'Grade 1 or Grade 2', 'Continue avelumab therapy', 'Continue hormone', 'endocrinopathies', 'Endocrinology consult if needed', 'replacement/suppression and', '(hypothyroidism,', 'monitoring of endocrine', 'hyperthyroidism, adrenal', 'Start thyroid hormone replacement', 'function as appropriate.', 'insufficiency, type I diabetes', 'therapy (for hypothyroidism),', 'mellitus)', 'anti-thyroid treatment (for', 'hyperthyroidism), corticosteroids', '(for adrenal insufficiency) or insulin', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '34']\n\n###\n\n", "completion": "END"}